Search for a command to run...
Ben Lamm discusses Colossal Biosciences' groundbreaking work in de-extinction, focusing on bringing back dire wolves through genetic engineering and highlighting the potential for conservation, scientific advancement, and inspiring future generations.
D.A. Wallach, a former musician turned biotech investor, discusses the unique challenges of investing in biotechnology, including low probabilities of drug success, the potential of AI, and the evolving global landscape of pharmaceutical innovation.
Eight Sleep's CEO Matteo Franceschetti discusses how his company is using AI and temperature control technology to improve sleep quality, develop a revolutionary sleep product, and potentially transform consumer health.
An interview with Lada Nuzhna, founder of General Control, exploring her journey in biotech, the challenges of developing aging therapies, and her mission to engineer epigenetic medicines that could potentially extend human lifespan.
In this episode, Preston Pysh and Seb Bunney explore David Sinclair's book "Lifespan", discussing the information theory of aging, epigenetics, Yamanaka factors, and the potential for science to slow or reverse the aging process through cellular repair and regeneration.
Celine Halioua discusses her company Loyal's groundbreaking work developing a daily pill for dogs that could extend their lifespan by at least one year, with the first therapy potentially available in 2026 and the potential to pave the way for human longevity research.